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Abstract
 
I
 
k
 
B kinase (IKK) 
 
a 
 
and 
 
b
 
 phosphorylate I
 
k
 
B proteins and activate the transcription factor, nu-
clear factor (NF)-
 
k
 
B. Although both are highly homologous kinases, gene targeting experi-
ments revealed their differential roles in vivo. IKK
 
a 
 
is involved in skin and limb morphogenesis,
whereas IKK
 
b
 
 is essential for cytokine signaling. To elucidate in vivo roles of IKK
 
a
 
 in hemato-
poietic cells, we have generated bone marrow chimeras by transferring control and IKK
 
a
 
-defi-
 
cient fetal liver cells. The mature B cell population was decreased in IKK
 
a
 
2
 
/
 
2
 
 chimeras.
IKK
 
a
 
2
 
/
 
2
 
 chimeras also exhibited a decrease of serum immunoglobulin basal level and impaired
antigen-specific immune responses. Histologically, they also manifested marked disruption of
germinal center formation and splenic microarchitectures that depend on mature B cells.
IKK
 
a
 
2
 
/
 
2
 
 B cells not only showed impairment of survival and mitogenic responses in vitro, ac-
companied by decreased, although inducible, NF-
 
k
 
B activity, but also increased turnover rate in
 
vivo. In addition, transgene expression of 
 
bcl
 
-2 could only partially rescue impaired B cell devel-
opment in IKK
 
a
 
2
 
/
 
2
 
 chimeras. Taken together, these results demonstrate that IKK
 
a
 
 is critically
involved in the prevention of cell death and functional development of mature B cells.
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Introduction
 
The nuclear factor (NF)
 
1
 
-
 
k
 
B family of transcription factors
plays critical roles in the activation of inflammatory im-
mune responses (1, 2). In resting cells, NF-
 
k
 
Bs associate
with I
 
k
 
Bs and are retained in the cytoplasm as inactive
forms. Proinflammatory stimuli, such as LPS, IL-1, or
TNF-
 
a
 
, cause phosphorylation and degradation of I
 
k
 
Bs,
which lead to NF-
 
k
 
B activation. The protein kinases that
phosphorylate I
 
k
 
B have been identified by three indepen-
dent groups (3–7). Two I
 
k
 
B kinases (IKKs), IKK
 
a
 
 and
IKK
 
b
 
, are main components of the I
 
k
 
B kinase complex
and homologous with each other in the amino acid struc-
tures. Both contain a kinase domain, a leucine zipper, and a
helix-loop-helix. However, gene targeting experiments re-
vealed that they function differentially depending on the
tissue. IKK
 
a
 
 is essential for limb patterning and for epider-
mal keratinocyte proliferation and differentiation (8–10).
Meanwhile, IKK
 
b
 
-deficient mice showed a massive apop-
tosis of hepatocytes (11–13). Furthermore, IKK
 
b
 
, but not
IKK
 
a
 
, was found to be essential for NF-
 
k
 
B activation by
proinflammatory cytokines.
B lineage cells also contain NF-
 
k
 
B activity, which can
be augmented by LPS or CD40 ligation. All known mam-
malian members of the NF-
 
k
 
B/Rel transcription factor
family, including p50(NF-
 
k
 
B1), p52(NF-
 
k
 
B2), p65(RelA),
RelB, and c-Rel, are expressed in B cells (14–18). Gene
targeting of these components caused various levels of im-
pairment of B cell generation and function (19–28). How-
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B Cell Abnormality in IKK
 
a
 
 Deficiency
 
ever, because IKK
 
a
 
- and IKK
 
b
 
-deficient mice died in an
early neonatal period, it is unclear whether IKK
 
a
 
 or IKK
 
b
 
is involved in NF-
 
k
 
B activation in B lineage cells.
To investigate how IKK
 
a
 
 is involved in lymphocytes,
we have established bone marrow (BM) chimeras with a
transfer of fetal liver cells from mice obtained by intercross-
ing IKK
 
a
 
1
 
/
 
2 
 
mice. IKK
 
a
 
2
 
/
 
2
 
 chimeras showed a reduction
of mature B cell population, impairment of basal and Ag-
specific Ig production, and disruption of splenic microar-
chitecture including germinal center (GC) formation. Our
results revealed the critical roles of IKK
 
a
 
 in peripheral B
cell survival and maturation.
 
Materials and Methods
 
Generation of BM Chimeras.
 
Generation of IKK
 
a
 
2
 
/
 
2
 
 mice
was described previously (10). H2K-
 
bcl
 
-2 transgenic (tg) mice
overexpressing Bcl-2 (29) were provided by Dr. I. Weissman
(Stanford University, Stanford, CA). IKK
 
a
 
1
 
/
 
2
 
 mice were inter-
crossed to obtain embryos with IKK
 
a
 
1
 
/
 
1
 
, IKK
 
a
 
1
 
/
 
2
 
, or IKK
 
a
 
2
 
/
 
2
 
genotype. 
 
bcl
 
-2-tg-IKK
 
a
 
2
 
/
 
2
 
 embryos were obtained from 
 
bcl
 
-2-
tg-IKK
 
a
 
1
 
/
 
2
 
 
 
3 
 
IKK
 
a
 
1
 
/
 
2
 
 mating. For each chimera, 5–10
 
 3 
 
10
 
6
 
fetal liver cells from the embryos at day 13.5–15.5 of gestation
were transferred intravenously into a recombination activating
gene (RAG)2-deficient C57BL/6 (B6) mice (30) that had re-
ceived 12 Gy from an x-ray irradiation system, MBR-1520R
(Hitachi Medical Corporation) before transfer, as described previ-
ously (31). The recipient mice were given 1 mg/ml neomycin
sulfate and 1,000 U/ml polymyxin B in their drinking water after
irradiation and analyzed 6–10 wk after reconstitution.
 
Flow Cytometric Analysis.
 
Single cell suspensions were incu-
bated first with anti-CD16/32 to minimize nonspecific staining
and stained with cocktails of mAbs conjugated to FITC, PE, or
biotin for 20 min at 4
 
8
 
C. The biotinylated Abs were developed
with streptavidin conjugated to PE or Cychrome. All mAbs, ex-
cept PE-labeled anti-IgD (Southern Biotechnology Associates,
Inc.), were purchased from BD PharMingen. Flow cytometric
analysis was performed using a FACSCalibur™ (Becton Dickin-
son) with CELLQuest™ software (Becton Dickinson).
 
Analysis for Cell Survival.
 
Cells were cultured at 2
 
 3 
 
10
 
6
 
 per
ml in 24-well plates for the indicated periods with or without 25
 
m
 
g/ml LPS (055:B5; Difco) or 0.5 
 
m
 
g/ml anti-CD40 (BD
PharMingen). Harvested cells were stained with PE-B220 and
further stained with annexin-V-FLUOS staining kit (Boehringer)
by following the manufacturer’s protocol. Stained cells were ana-
lyzed with a FACSCalibur™.
 
Lymphocyte Activation in Culture.
 
Splenic B cells were purified
by depletion of non-B cells with a Magnetic Cell Sorter (MACS;
Miltenyi Biotec). In brief, splenocytes were first stained with bi-
otinylated anti-CD43 mAb and incubated with streptavidin mi-
crobeads. Then CD43
 
2 cells were purified on MACS AS col-
umn and used as splenic B cells (32). Splenic T cells were also
purified by MACS with biotinylated anti-CD8 mAb, and CD4
and streptavidin microbeads. The resulting B and T cell prepara-
tions contained .90% B2201 cells and 95% CD31 cells, respec-
tively, as determined by FACS®. The B cells (105 cells/well) from
chimeras were cultured in complete RPMI 1640 (RPMI 1640
medium supplemented with 10% FCS, 2-ME, penicillin, and
streptomycin) with or without 25 mg/ml LPS, 0.5 mg/ml anti-
CD40, 0.5 mg/ml anti-CD40 plus 200 U/ml IL-4, or 25 mg/ml
LPS plus 0.5 mg/ml anti-CD40. After 48 h, they were pulsed
with 0.2 mCi of [3H]thymidine (NEN Life Science Products) and
cultured for a further 15 h. [3H]Thymidine incorporation was
measured with a liquid scintillation counter, Top Count (Packard
Instrument Co.).
Labeling Cells with 5-Bromo-29-deoxyuridine. Chimeric mice
were fed with light-protected drinking water containing 1 mg/ml
5-bromo-29-deoxyuridine (BrdU; Wako) for 4 d. BrdU-labeled
cells were detected by flow cytometric analysis with FITC-conju-
gated anti-BrdU Ab, 3D4 (BD PharMingen). In brief, splenic
cells were stained with PE-B220 and fixed with PBS containing
1% paraformaldehyde and 0.01% Tween 20 for 24 h at 48C. Cells
were washed and incubated for 1 h at 378C in 40 mM Tris-HCl,
pH 8.0, containing 10 mM NaCl, 6 mM MgCl2, and 50 Kuniz
units of DNase I (Sigma-Aldrich). Then cells were washed and
incubated with FITC–anti-BrdU or FITC-conjugated control
Ab in the presence of 0.5% Tween 20. Stained cells were ana-
lyzed with a FACSCalibur™.
Electrophoretic Mobility Shift Assay. Splenic B (CD432) cells
from IKKa1/1 and IKKa2/2 mice were incubated with or with-
out 25 mg/ml LPS or 0.5 mg/ml anti-CD40 for 1.5 h. Then,
whole cell lysates were prepared, and NF-kB DNA binding ac-
tivities were analyzed as described previously (33). For supershift
analysis, Abs for each NF-kB component (Santa Cruz Biotech-
nology, Inc.) were incubated with the lysates before the addition
of an NF-kB oligonucleotide probe.
Reverse Transcriptase PCR for A1. Purified splenic B cells
were incubated with or without 25 mg/ml LPS or 0.5 mg/ml
anti-CD40 for 2 h. Extraction of total RNAs, reverse transcrip-
tion, and PCR analysis were performed as described previously
(31). Primers for A1 were as follows: sense primer, 59-TCATG-
CATATCCACTCCCTGGCTGAGC-39; and antisense primer,
59-GTCCTGTCATCTGCAGAAAAGTCAGCC-39.
Serum Ig Level and T Cell–dependent Immune Responses. Se-
rum Ig isotype concentrations of RAG2-deficient chimeras were
analyzed by ELISA as described (34). Abs and standard Igs were
purchased from Southern Biotechnology Associates, Inc. For T
cell–dependent immune responses, mice were immunized with
100 mg/head of alum-precipitated chicken g-globulin (CG) cou-
pled to 4-hydroxy-3-nitro-phenylacetyl (NP) and bled at the in-
dicated days. The serum titers of NP-specific IgM and IgG1 were
determined by ELISA as described (34). Statistical analysis was
performed with the unpaired Student’s t test.
Histological Analysis of Splenic Sections. Mice were killed 14 d
after immunization with NP-CG, and the spleens were removed
promptly. Each spleen was divided into two pieces, one piece for
hematoxylin and eosin (HE) stain and the other for immunohis-
tochemistry. For HE stain, spleen tissues were fixed in 10% buf-
fered formalin, pH 7.2, and embedded in paraffin. Deparaffinized
sections (4 mm thick) were then stained with HE. For immuno-
histochemistry, freshly dissected spleens were covered with Tis-
sue-Tek OCT compound (Miles, Inc.) and quickly frozen in liq-
uid nitrogen. Frozen sections (4 mm thick) were then fixed with
ice cold acetone, and incubated in 3% H2O2 in 50% methanol for
30 min to inactivate internal peroxidase. After washing with PBS,
the sections were incubated with normal goat serum or normal
horse serum (Vector Laboratories) to block nonspecific binding
of Abs, and subsequently with the following reagents: anti-B220
(BD PharMingen), anti-IgD (Southern Biotechnology Associates,
Inc.), biotin-conjugated peanut agglutinin (PNA; Seikagaku ko-
gyo), follicular dendritic cell (FDC)-M1 (reference 35; a gift from
Dr. M.H. Kosco-Vilbois, Serono Pharmaceutical Research In-
stitute, Geneva, Switzerland), biotinylated F4/80 (Serotec),
MOMA-1 (Serotec), antisialoadhesin (Serotec), or rabbit anti–
BST-1 serum (reference 36; a gift from Drs. T. Hirano and K.419 Kaisho et al.
Ishihara, Osaka University). For negative controls, rabbit pre-
immune serum or isotype-matched rat IgGs were used. After
washing with PBS, sections were further incubated with biotin-
conjugated, goat anti–rabbit IgG (Vector Laboratories) or rabbit
anti–rat Igs (Dako). Immunoreacted cells were then visualized by
using a Vectastain ABC Elite kit (Vector Laboratories) and diami-
nobenzine tetrahydrochloride (Sigma-Aldrich). The sections
were lightly counterstained with hematoxylin.
Results
Decrease of Mature B Cell Population in IKK2/2 Chimeras.
IKKa-deficient mice die in an early neonatal period
(8–10). To analyze roles of IKKa in hematopoietic cells,
BM chimeras were established and analyzed for lympho-
cyte populations in various organs with flow cytometry
(Fig. 1). In the peripheral blood (PB), B2201 cells in
IKKa2/2 chimeras significantly decreased compared with
those in IKKa1/1 chimeras. Concomitant with decrease in
the B cell population, the CD31 T cell population in-
creased in IKKa2/2 chimeras (Fig. 1 A). Also in the spleen,
decrease of B2201 and increase of CD31 T cells were ob-
served in IKKa2/2 chimeras (Fig. 1 C). The results from
IKKa1/2 chimeras were similar to IKKa1/1 chimeras (data
not shown). Mean total spleen cell numbers from 18 con-
trol (IKKa1/1 and 1/2) and 19 2/2 chimeras were 2.1 3
107 and 1.2 3 107, respectively. Therefore, the increase of
CD31 T cell population percentages is not because of an
increase of its absolute numbers. Furthermore, CD4 versus
CD8 staining of thymus and spleen revealed no significant
differences between IKKa1/1 and IKKa2/2 chimeras, in-
dicating that T cell development proceeds normally in the
absence of IKKa (data not shown).
Next, we analyzed splenic B cell maturation status in chi-
meras (Fig. 1 C). Peripheral B cell development proceeds
from immature IgMhighIgDhigh to mature IgMlowIgDhigh cells
(37, 38). The decrease of B cell numbers in IKKa2/2 chi-
meras was more prominent in IgMlowIgDhigh cells than in
IgMhighIgDhigh cells. Given the decrease of total spleen cell
numbers, the IgMhighIgDhigh cell population in IKKa2/2
chimeras was also reduced approximately twofold. B cell
maturation is also characterized by the upregulation of
CD21 and CD23 and the downregulation of heat stable an-
tigen (HSA; reference 39). This marker analysis (Fig. 1 C),
together with IgM versus IgD staining, clearly demonstrates
that mature B cells were more severely decreased than im-
mature B cells in the spleen of IKKa2/2 chimeras.
We also analyzed early B cell development in the BM
(Fig. 1 B). The population size of pro-B (CD431
IgM2B2201), pre-B (CD432IgM2B2201), and immature
B (CD432IgM1B220low) cells was comparable between
IKKa1/1 and IKKa2/2 chimeras. However, mature recir-
culating B (CD432IgM1B220high) cells (40) significantly
decreased in IKKa2/2 chimeras (7.0%) compared with
those in IKKa1/1 chimeras (29.3%).
Enhanced Cell Death of In Vitro IKKa2/2 B Cells. NF-
kB activity has been shown to mediate antiapoptotic activ-
ity in various cells including B cells (41, 42). We have ex-
Figure 1. Mature B cell decrease in IKKa2/2 RAG2-deficient B6 chi-
meras. Single cell suspensions from (A) PB, (B) BM, and (C) spleen were
stained with the indicated Abs and analyzed using a FACSCalibur™ with
CELLQuest™ software. The percentages of the quadrants or enclosed ar-
eas are indicated by numbers. For BM, triple color analysis was per-
formed, and CD43 versus B220 and IgM versus B220 profiles are shown
for IgM2 and CD432 lymphoid cells, respectively. In C, data from
IKKa2/2 chimeras with transgene expression of bcl-2 are also shown.
Four independent experiments were performed with similar results. One
representative experiment is shown.420 B Cell Abnormality in IKKa Deficiency
amined survival of B lineage cells in both IKKa1/1 and
IKKa2/2 chimeras with annexin V binding activity. PB
from the chimeras was cultured in vitro in the absence of
mitogens for the indicated periods and analyzed for their
annexin V binding activity with FACS® (Fig. 2, A and B).
Before culture (0 h), percentages of B2201annexin1 cells in
PB were higher in IKKa2/2 chimeras (3.3/7.1 1 3.3 5
31.7%) than in IKKa1/1 chimeras (4.3/4.3 1 26.2 5
14.1%) (Fig. 2, A and B). B2201annexin1 cells reached
.95% of the total B2201 cells in IKKa2/2 chimeras after
24 h of culture, whereas they were 63.4 and 83.7% in
IKKa1/1 chimeras after 24 and 48 h of culture, respec-
tively. Likewise, survival of splenic B cells was severely im-
paired in IKKa2/2 chimeras before and throughout the
culture period (Fig. 2, A and B).
Mitogens such as LPS or anti-CD40 can induce B cell
activation by inducing NF-kB activation. At 48 h,
annexin1 B cell percentages of LPS-stimulated IKKa1/1
splenocytes (57.3%) were less than those of unstimulated
ones (68.9%; Fig. 2 B). However, LPS could not decrease
annexin1 B cell percentages in IKKa2/2 chimeras. Fur-
thermore, after 48 h of stimulation with anti-CD40,
annexin1 B cell percentages in IKKa1/1 splenocytes de-
creased to 21.2%, while those in IKKa2/2 splenocytes, al-
though slightly reduced, remained at 71.3%. Thus, at any
culture periods, with or without mitogens, cell death was
significantly augmented in IKKa2/2 B cells.
Increased Turnover of In Vivo IKKa2/2 B Cells. In vivo
B cell turnover rate was evaluated in chimeras. BrdU-
labeled B2201 cells were 10.9 and 8.6% in the spleens of
IKKa1/1 and IKKa2/2 chimeras, respectively (Fig. 2 C).
Considering the decrease of B cell percentages in IKKa2/2
chimeras, it can be reasonably assumed that about two
times more percentages of B cells were labeled with BrdU
in IKKa2/2 chimeras than in IKKa1/1 chimeras. The re-
sults clearly suggest that B cell turnover in vivo is enhanced
in the absence of IKKa.
Impaired Mitogenic Responses of IKKa2/2 B Cells. We
have analyzed splenic B cell responses to LPS and anti-
CD40 with thymidine incorporation (Fig. 3 A). The incor-
poration of IKKa2/2 B cells stimulated with LPS or anti-
CD40 was z5–10 times less than that of IKKa1/1 B cells.
Simultaneous stimulation with LPS and anti-CD40 could
enhance the proliferation of IKKa2/2 B cells, but not to
the same level as IKKa1/1 B cells (Fig. 3 A). Furthermore,
blast formation by LPS or anti-CD40 was severely attenu-
ated in IKKa2/2 B cells (Fig. 3 B). In contrast, thymocytes
and splenic T cells derived from IKKa2/2  chimeras
showed normal proliferative responses to T cell mitogens
such as IL-2 plus anti-CD3 or IL-2 plus Con A (data not
shown).
Impaired NF-kB Activation in IKKa2/2 B Cells. We
next analyzed NF-kB activity in IKKa1/1 and IKKa2/2
splenic B cells with or without LPS or anti-CD40 (Fig. 4).
Although the mitogens could enhance the NF-kB DNA
binding activity in both IKKa1/1 and 2/2 B cells, the mag-
nitude of the activity was decreased in IKKa2/2 B cells
(Fig. 4 A). Anti-CD40–induced NF-kB activation was
more severely impaired than the LPS-induced one in
IKKa2/2 B cells.
To determine the components of NF-kB complexes, we
performed a supershift analysis by using specific Abs (Fig. 4
B). In IKKa1/1 B cells, anti-p50 supershifted nearly all the
LPS-induced complexes, while anti-p65 did parts of them.
Hence, the remaining complex in IKKa1/1 B cells with
anti-p65 treatment seems to correspond mainly to p50/p50
Figure 2. Impaired survival in vitro and
increased turnover in vivo of IKKa2/2 B
cells. (A and B) PB and splenocytes from
IKKa1/1 and IKKa2/2 RAG2-deficient
B6 chimeras were cultured in complete
RPMI 1640 in the absence or presence of
mitogens for the indicated periods and
stained with FITC–annexin V and PE-
B220. Percentages of annexin1 B cells were
calculated by dividing percentages of
B2201annexin1 cells by those of total B
(B2201annexin1 and B2201annexin2) cells
and shown as bar graphs in B. (C) Increased
B cell turnover in IKKa2/2 chimeras. The
turnover of splenic B cells was determined
by BrdU incorporation. Numbers represent
percentages of the quadrants. Experiments
were independently performed three times
with similar results. One representative ex-
periment is shown.421 Kaisho et al.
homodimer. The results showed that LPS can mainly in-
duce p50/p50 homodimer and p50/p65 heterodimer as
NF-kB complexes. In addition, other components also
contributed to NF-kB binding activity to some extent be-
cause anti-p52, –c-Rel, and -RelB Abs partially inhibited
the binding. As observed in IKKa1/1 B cells, the detect-
able NF-kB complex in IKKa2/2 B cells showed a similar
supershift pattern, indicating that the composition of resid-
ual NF-kB complexes in IKKa2/2 B cells is not grossly
different from that in IKKa1/1 B cells.
Decreased Basal Level of A1 Expression in IKKa2/2 B
Cells. NF-kB is involved in the expression of antiapop-
totic genes. For example, c-Rel is essential for not only
basal but also mitogen-induced expression of A1 (43). A1
expression remains low during BM B cell development,
but is upregulated 10-fold as cells maturate into a long-
lived peripheral B cell stage, suggesting that constitutive A1
expression is critically involved in resting mature B cell sur-
vival (44). Therefore, we examined A1 gene expression in
IKKa1/1 and IKKa2/2 B cells with or without mitogens.
LPS or anti-CD40 could enhance A1 gene expression not
only in IKKa1/1 B cells but also in IKKa2/2 B cells (Fig.
5). However, basal expression of A1 was lower in IKKa2/2
B cells than in IKKa1/1 B cells.
Partial Rescue of Impaired B Cell Development in IKKa2/2
Chimeras by Bcl-2 Expression. To assess whether the pre-
vention of IKKa2/2 B cell apoptosis can restore peripheral
B cell development, IKKa2/2 chimeras expressing the bcl-2
transgene were established and analyzed by FACS® (Fig. 1
C). Total spleen cell numbers of bcl-2-tg-IKKa2/2 chime-
ras (8.9 3 107, n 5 5) were prominently increased com-
pared with IKKa2/2 chimeras. CD3 versus B220 staining
revealed that Bcl-2 expression corrected the ratio of B to T
cells in IKKa2/2 chimeras. Next, B cell maturation status
was analyzed with several markers. Although percentages
of IgMlowIgDhigh and IgMhighIgDhigh cell populations in-
creased, the ratio of IgMlowIgDhigh to IgMhighIgDhigh cell
population in bcl-2-tg-IKKa2/2 chimeras was not signifi-
cantly different from IKKa2/2 chimeras. Furthermore, in
bcl-2-tg-IKKa2/2 chimeras, CD21 expression on B2201
cells remained as low as IKKa2/2 chimeras. However,
CD23 upregulation and HSA downregulation were re-
stored by Bcl-2 expression. Thus, bcl-2 transgene expres-
sion could enhance B lineage cell expansion, but only par-
tially restore B cell maturation in the absence of IKKa.
Figure 3. Impaired mitogenic responses of IKKa2/2 B cells. (A)
Splenic B cells from IKKa1/1 and IKKa2/2 RAG2-deficient B6 chime-
ras were cultured in the absence or presence of mitogens for 72 h and an-
alyzed for their [3H]thymidine incorporation. The data indicate means 6
SD of triplicate samples of one representative experiment. (B) Splenocytes
from IKKa1/1 and IKKa2/2 RAG2-deficient B6 chimeras were cultured
with LPS or anti-CD40 for 48 h. Forward scatter (FSC) and side scatter
(SSC) of harvested cells were analyzed by FACS®. Blasts are indicated by
enclosed areas. Experiments were independently performed three times
with similar results. One representative experiment is shown.
Figure 4. NF-kB DNA binding activity in IKKa1/1 and IKKa2/2 B
cells. (A) Splenic B cells were stimulated with or without 25 mg/ml LPS
(L) or 0.5 mg/ml anti-CD40 (40) for 1.5 h. The whole cell lysates were
prepared and NF-kB activity was determined by electrophoretic mobility
shift assay. (B) LPS-induced NF-kB complexes were analyzed by super-
shift analysis. Specific NF-kB complexes are indicated by arrowheads.
*Nonspecific binding. Similar results were obtained from three indepen-
dent experiments.
Figure 5. Decrease of basal A1
gene expression in IKKa2/2 B
cells. A1 expression was analyzed
in IKKa1/1 or IKKa2/2 B cells
with or without LPS (L) or anti-
CD40 (40) stimulation through
reverse transcription PCR analy-
sis. Basal A1 gene expression was
determined by amplification with
30 cycles. As controls, data for
b-actin expression are shown. M,
F3174/HaeIII digest marker.422 B Cell Abnormality in IKKa Deficiency
Decreased Serum Ig Levels and Impaired T Cell–dependent
Immune Responses in IKKa2/2 Chimeras. We further investi-
gated immune functions of IKKa1/1 and IKKa2/2 chime-
ras. Basal production of all Ig isotypes in IKKa2/2 chimeras
was reduced to 1/50 or less of those in IKKa1/1 chimeras
(P , 0.0001, Fig. 6 A). Furthermore, T cell–dependent
immune responses were severely impaired in IKKa2/2 chi-
meras because Ag-specific IgM and IgG1 levels of IKKa2/2
chimeras were ,1/10 of IKKa1/1 chimeras (Fig. 6 B,
anti-NP IgM at day 7, P , 0.001; anti-NP IgM at day 14
and IgG1 at day 7 and 14, P , 0.0001).
Histological analysis was performed to evaluate the GC
formation and splenic microarchitecture 14 d after immu-
nization (Fig. 7). HE, B220, and IgD staining revealed the
well-developed GC with clear B cell areas in control chi-
meras. In contrast, in IKKa2/2 chimeras, poor GC forma-
tion was revealed with HE stain, although B2201 or IgD1
cells clearly formed B cell areas. Remarkably, PNA1 cell
clusters, which represent GC B cells, were not detected at
all in the spleen of IKKa2/2 chimeras.
To further investigate the alterations of the splenic mi-
croarchitecture in IKKa2/2 chimeras, tissue sections were
also stained with markers for FDCs or macrophages (Fig. 7
B). FDC clusters, defined by FDC-M1 (35), were readily
detected in IKKa1/1 chimeras but not in IKKa2/2 chime-
ras. A stromal cell antigen, BST-1/Bp-3, is expressed on
stromal cells in the T zone and follicles (45–47), which in-
clude precursors of FDCs (48). Expression patterns of BST-
1/Bp-3 were equivalent in IKKa 1/1 and IKKa2/2 chi-
meras, suggesting that there are FDC precursors in IKKa2/2
chimeras. Meanwhile, marginal metallophilic macrophages,
identified by MOMA-1 or an antisialoadhesin Ab, were
clearly detected in IKKa1/1 chimeras but not in IKKa2/2
chimeras. Furthermore, F4/801 red pulp macrophages in
IKKa1/1 chimeras were clearly excluded into the red pulp,
while some F4/801 cells in IKKa2/2 chimeras migrated
into the white pulp. Collectively, these histological findings
clearly indicate that IKKa is critical not only for GC for-
mation but also for establishing the splenic microarchi-
tecture.
Discussion
We have generated BM chimeras to elucidate in vivo
roles of IKKa in lymphocytes. Although certain NF-kB
subunit-deficient mice showed T cell defects in population
size or proliferative responses (24, 25, 28, 49), IKKa2/2
chimeras did not, indicating that IKKa is not essential for
T cell development or proliferation. This is also consistent
with previous findings, including ours, that cytokine- or T
cell receptor–induced NF-kB activation is dependent on
IKKb, but not on IKKa in T lineage cells (10, 50). How-
ever, we cannot exclude the possibility that IKKa is in-
volved in some T cell functions.
Our results clearly demonstrate that IKKa is involved in
mature B cell development and function, but not in early B
cell development. NF-kB components are developmentally
regulated in B lineage cells (14, 15). Gene targeting re-
vealed that an individual NF-kB component plays its own
critical roles in a B cell stage–specific manner. For example,
BM chimeras transplanted with p50/p65 double knockout
fetal liver cells lacked pro-B cells (27), indicating that the
p50/p65 heterodimer is essential for early B lymphopoiesis.
On the contrary, mutant mice lacking c-Rel showed nor-
mal BM B cell development, but manifested impairment of
mitogenic responses, basal production of all Ig isotypes, and
T cell–dependent immune responses (28). Although p50 is
a major component for NF-kB throughout B cell develop-
ment, p50-deficient mice showed impairment of mature B
cell functions: low responses to LPS, reduction of some
isotypes of serum Igs (IgG1, IgG2b, IgA, and IgE), and im-
pairment of immune responses (19). Therefore, the pheno-
type of IKKa2/2 chimeras was more similar to c-Rel– or
p50-deficient mice than to p50/p65-deficient mice, in the
respect that peripheral, not BM, B cell development is im-
paired.
Mutant mice lacking other NF-kB components also
showed a similar phenotype to IKKa2/2 chimeras. For ex-
ample, targeting of p52 results in a decrease of B cells, low
responses to B cell mitogens, and impaired GC formation
(23, 26). An IkB family member, Bcl-3, can function as a
potent coactivator with p50/p50 or p52/p52 homodimers
(51, 52). Bcl-3–deficient mice also showed decrease of B
cells and impairment of GC formation (53, 54). However,
Figure 6. Decreased Ig production and impaired T cell–dependent im-
mune responses in IKKa2/2 chimeras. (A) Serum Ig isotype levels in un-
immunized, IKKa1/1, IKKa1/2, and IKKa2/2 RAG2-deficient B6 chi-
meras. Serum Ig titers were determined by isotype-specific ELISA. (B)
Immune responses to the T cell–dependent Ag, NP-CG. IKKa1/1 and
IKKa2/2 RAG2-deficient B6 chimeras were immunized with alum-pre-
cipitated NP-CG and bled at the indicated days. NP-specific IgM and
IgG1 titers were determined by ELISA. Bars indicate mean values.423 Kaisho et al.
GC formation was restored by the transfer of p52- or Bcl-
3–deficient lymphocytes into irradiated RAG1-deficient
mice (26). Thus, p52 and Bcl-3 play critical roles in non-
BM stromal cells, while IKKa does in lymphocytes despite
their similar phenotype.
Mutant mice established so far lacking a single NF-kB
component showed an apparently less severe phenotype
than IKKa2/2 chimeras. For example, the B cell popula-
tion is not decreased in c-Rel– or p50-deficient mice. In
addition, not all isotypes of Ig production were impaired
and GC formation was observed in p50-deficient mice (19,
26, 53). Double knockout mice manifested more severe
phenotype than single knockout mice, exemplified by p50/
p52 double knockout mice with severe mature B cell de-
fects (25). Furthermore, tg mice harboring a dominant neg-
ative form of IkB, in which function of more than one NF-
kB component is presumably attenuated, showed mature B
cell decrease as in IKKa2/2 chimeras (55). Given these
findings, it can be assumed that IKKa is critically involved
in the activation of several NF-kB components in B cells.
Histologically, B2201 or IgD1 staining indicates that
IKKa expression in hematopoietic cells is dispensable for
T–B compartmentalization. However, IKKa2/2chimeras
showed loss of GC marker such as PNA or FDC-M1 with
normal BST-1/Bp-3 expression. GC formation proceeds
with FDC generation from FDC precursors expressing
BST-1/Bp-3 in a mature B cell–dependent manner (48).
Therefore, these histological findings are consistent with
mature B cell decrease in IKKa2/2 chimeras.
What brings about decrease of mature B cells in the ab-
sence of IKKa? It is possible that IKKa is critically in-
volved in survival, mitogenic proliferation, or development
in B cells. Cell turnover analysis in vivo and annexin stain-
ing in vitro (Fig. 2) clearly indicate enhanced cell death of
IKKa2/2 B cells. In addition, impaired mitogenic re-
sponses were also observed in IKKa2/2 B cells (Fig. 3).
Thus, IKKa should be critical not only for preventing B
cell death but also for B cell mitogenic responses. Similar
abnormalities were found in some NF-kB mutant mice.
For example, p502/2 B cells manifested enhancement of
apoptosis (22). Furthermore, B cell mitogenic responses
were impaired in mutant mice lacking p50, c-Rel, or Rel-B
(19–21, 24, 28).
We further addressed whether IKKa deficiency can lead
to B cell developmental block. To rescue B cells from apop-
tosis, we have introduced bcl-2 transgene expression into the
IKKa2/2 background. Bcl-2 could restore the ratio of B to
T cells, CD23 upregulation, and HSA downregulation, but
neither differentiation into IgMlowIgDhigh cells nor CD21
upregulation in IKKa2/2 chimeras. Partial restoration of
Figure 7. (A) Impaired GC formation in IKKa2/2 chimeras. IKKa1/1 and IKKa2/2 RAG2-deficient B6 chimeras were immunized with alum-pre-
cipitated NP-CG and killed 14 d after injection. Splenic sections were stained with HE or immunostained with B220, anti-IgD, or PNA. (B) Impairment
of splenic microarchitecture in IKKa2/2 chimeras. Frozen sections were stained with FDC-M1, F4/80, MOMA-1, or antisialoadhesin mAbs or rabbit
anti–BST-1/Bp-3 antiserum. Scale bars, 200 mm.424 B Cell Abnormality in IKKa Deficiency
IKKa2/2 B cell development with bcl-2 transgene expres-
sion indicates that IKKa is critically involved in peripheral
B cell development. It is also possible that the developmen-
tal defect caused by IKKa deficiency can make B cells sus-
ceptible to apoptosis and hyporesponsive to mitogens.
B cell receptor (BCR) signaling is critical for mainte-
nance of the peripheral B cell population (56). Once B cells
lack surface Ig, they die through an apoptotic pathway (56).
Mature B cell reduction is also observed in mutant mice
lacking BCR signaling molecules such as Bruton’s tyrosine
kinase (BTK; references 57, 58), B cell linker protein
(BLNK/SLP-65; references 59, 60), phosphoinositide
3-kinase p85a (61, 62), or phospholipase C-g2 (63, 64).
Notably, enhanced apoptosis of B lineage cells was also de-
tected in the xid mice carrying the mutation in BTK (38).
BTK is essential for coupling the BCR signal to NF-kB ac-
tivation (65, 66). In addition, BCR signaling can activate
phosphoinositide 3-kinase and a serine/threonine kinase,
Akt (67), which can induce phosphorylation of IKKa (68).
These findings suggest the possibility that IKKa is involved
in BCR signaling.
Several lines of evidences suggest that IKKb, but not
IKKa, is mainly involved in cytokine-induced NF-kB ac-
tivation (8–13). This seems inconsistent with our finding
that NF-kB activation by LPS or anti-CD40 was decreased
in IKKa2/2 B cells. However, activation is still inducible
and sufficient for partial responses to LPS and anti-CD40
(Figs. 2 B and 3 A) and A1 gene induction (Fig. 5), indicat-
ing that IKKb can still function without IKKa.
The inducible expression of A1 was also observed in
p50-deficient B cells, which manifested enhanced apoptosis
(22, 43). In contrast, c-Rel–deficient B cells manifested im-
paired induction of A1 expression but no enhanced apop-
tosis (22, 43). This might suggest that similar molecular de-
fects, although unidentified, may underlie the augmented
cell death of p50- and IKKa-deficient B cells.
In conclusion, this study strongly suggests that IKKa
plays crucial roles in the survival, proliferative responses,
and maturation of peripheral B cells. The defects caused by
IKKa deficiency are most likely intrinsic to B cells, al-
though the possibility cannot formally be excluded that
dysfunction of BM-derived, non-B cells also contributes to
the phenotype of IKKa2/2 chimeras. It is unclear at
present which contributes more to the observed B cell de-
fects, disturbed maturation or dysfunction of already ma-
tured B cells. Although the molecular mechanism remains
to be clarified yet, IKKa is a critical molecule for maintain-
ing the mature B cell population.
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